Cargando…
Ivosidenib: First Global Approval
Ivosidenib (Tibsovo(®)) is a small molecule, orally available inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) that is being developed by Agios Pharmaceuticals for the treatment of cancer in patients with IDH1 mutations. The mutated form of the IDH1 enzyme produces a metabolite, 2-hy...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315051/ https://www.ncbi.nlm.nih.gov/pubmed/30209701 http://dx.doi.org/10.1007/s40265-018-0978-3 |